HK1077085A1 - Methods of producing influenza vaccine compositions - Google Patents

Methods of producing influenza vaccine compositions

Info

Publication number
HK1077085A1
HK1077085A1 HK05110886.1A HK05110886A HK1077085A1 HK 1077085 A1 HK1077085 A1 HK 1077085A1 HK 05110886 A HK05110886 A HK 05110886A HK 1077085 A1 HK1077085 A1 HK 1077085A1
Authority
HK
Hong Kong
Prior art keywords
methods
vaccine compositions
influenza vaccine
producing influenza
producing
Prior art date
Application number
HK05110886.1A
Other languages
English (en)
Inventor
George Robert Trager
George Kemble
Richard M Schwartz
Harshvardhan Mehta
Vu Truong-Le
Zhongying Chen
Alfred A Pan
Eric Tsao
Chiaoyin Kathy Wang
Luisa Yee
Palani Balu
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of HK1077085A1 publication Critical patent/HK1077085A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/147—Microfiltration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Water Supply & Treatment (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
HK05110886.1A 2003-02-25 2005-11-30 Methods of producing influenza vaccine compositions HK1077085A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45018103P 2003-02-25 2003-02-25
PCT/US2004/005697 WO2005014862A1 (en) 2003-02-25 2004-02-25 Methods of producing inflenza vaccine compositions

Publications (1)

Publication Number Publication Date
HK1077085A1 true HK1077085A1 (en) 2006-02-03

Family

ID=34135009

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05110886.1A HK1077085A1 (en) 2003-02-25 2005-11-30 Methods of producing influenza vaccine compositions

Country Status (9)

Country Link
US (5) US7262045B2 (xx)
EP (2) EP2481819A1 (xx)
JP (1) JP4617300B2 (xx)
KR (4) KR101251902B1 (xx)
CN (2) CN100582244C (xx)
AU (2) AU2004263813B8 (xx)
CA (2) CA2807534A1 (xx)
HK (1) HK1077085A1 (xx)
WO (1) WO2005014862A1 (xx)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
KR101229202B1 (ko) 2002-04-26 2013-02-01 메디뮨 엘엘씨 인플루엔자 바이러스의 생산을 위한 다중 플라스미드 시스템
CA2491145A1 (en) * 2002-07-03 2004-01-15 Basf Aktiengesellschaft Microorganisms and processes for enhanced production of pantothenate
US20060110406A1 (en) 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
KR101251902B1 (ko) 2003-02-25 2013-04-08 메디뮨 엘엘씨 인플루엔자 백신 조성물의 제조 방법
CA2529647C (en) 2003-06-16 2013-08-13 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
JP4771959B2 (ja) 2003-12-23 2011-09-14 メディミューン，エルエルシー インフルエンザウイルス作製のための多重プラスミド系
EP2821135A1 (en) * 2004-02-05 2015-01-07 EMD Millipore Corporation Porous adsorptive or chromatographic media
WO2006041819A1 (en) * 2004-10-06 2006-04-20 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
WO2006063053A2 (en) * 2004-12-08 2006-06-15 Medimmune Vaccines, Inc. Methods of producing influenza vaccine compositions
AU2005322353B2 (en) 2004-12-23 2011-09-01 Medimmune, Llc Non-tumorigenic MDCK cell line for propagating viruses
EP2441471B1 (en) 2005-03-08 2014-10-08 MedImmune, LLC Reassortant influenza viruses
MX2007012786A (es) * 2005-04-13 2008-01-11 Merial Ltd Ensayo para produccion de circovirus porcino.
WO2006130826A1 (en) * 2005-06-02 2006-12-07 Alza Corporation Method for terminal sterilization of transdermal delivery devices
US7790434B2 (en) * 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
RU2008101367A (ru) * 2005-06-21 2009-08-10 Медиммун, Ллк (Us) Способы и композиции для экспрессии отрицательной смысловой вирусной рнк в собачьих клетках
BRPI0614100A2 (pt) * 2005-08-03 2011-03-09 Immunogen Inc formulações de imunoconjugado lìquidas
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
US7534596B2 (en) * 2006-02-10 2009-05-19 Solohill Engineering, Inc. Method and device for producing vaccine
BRPI0710626A2 (pt) 2006-04-19 2011-08-16 Medimmune Llc ácido nucleico isolado, vetor de expressão, métodos para produzir um rna genÈmico da influenza e um vìrus da influenza recombinante, célula, método para gerar em células caninas cultivadas um vìrus de rna, vìrus da influenza, e, sequência de ácido nucleico isolado
GB0614460D0 (en) * 2006-07-20 2006-08-30 Novartis Ag Vaccines
RU2487935C2 (ru) 2006-09-15 2013-07-20 Медиммун, Ллк. Линии клеток почки собаки майдин-дэрби (mdck), поддерживающие рост вирусов до высоких титров, и способ применения этих клеток в биореакторе
SG177887A1 (en) * 2006-12-15 2012-02-28 Schering Plough Ltd Method for replicating influenza virus in culture
US8216588B2 (en) * 2007-03-09 2012-07-10 Otsuka Pharmaceuticals Co., Ltd. Lyophilized preparation comprising influenza vaccine, and method for preparation thereof
US8673613B2 (en) 2007-06-18 2014-03-18 Medimmune, Llc Influenza B viruses having alterations in the hemaglutinin polypeptide
US9433922B2 (en) * 2007-08-14 2016-09-06 Emd Millipore Corporation Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same
AU2008331673B2 (en) * 2007-11-12 2014-12-11 The Trustees Of The University Of Pennsylvania Novel vaccines against multiple subtypes of influenza virus
US20090130738A1 (en) * 2007-11-19 2009-05-21 Mikhail Kozlov Media for membrane ion exchange chromatography
EP2072058A1 (en) * 2007-12-21 2009-06-24 Avir Green Hills Biotechnology Research Development Trade Ag Modified influenza virus
JP2011184299A (ja) * 2008-07-02 2011-09-22 Asahi Kasei Medical Co Ltd モノクローナル抗体を含む製剤の製造方法
CN102215865B (zh) 2008-09-24 2013-10-30 米迪缪尼有限公司 病毒纯化方法
EP2344634A4 (en) 2008-09-24 2012-08-29 Medimmune Llc METHODS OF CELL CULTURE, AND PROPAGATION AND PURIFICATION OF VIRUSES
WO2010060921A1 (en) * 2008-11-25 2010-06-03 Avir Green Hills Biotechnology Research Development Trade Ag METHOD FOR PRODUCTION OF pH STABLE ENVELOPED VIRUSES
AU2009333208A1 (en) 2008-12-16 2010-07-08 Baxter Healthcare Sa Production of influenza vaccines
CN101450209B (zh) * 2008-12-31 2012-01-25 中国人民解放军军事医学科学院微生物流行病研究所 透皮免疫流感多价疫苗的制备及其方法
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
WO2011005769A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US20120077249A1 (en) * 2010-04-20 2012-03-29 Millipore Corporation Separation Of Virus And/Or Protein From Nucleic Acids By Primary Amines
US9610248B2 (en) 2010-07-06 2017-04-04 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
US8606750B2 (en) * 2010-11-12 2013-12-10 Life Technologies Corporation Systems and methods for laboratory assay validation or verification
EP2663288B1 (en) 2011-01-13 2022-12-21 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
BR112013017939B1 (pt) 2011-01-13 2022-11-16 Variation Biotechnologies Inc Composição imunogênica liofilizada termoestável, uso e método para preparação da mesma
WO2012136852A1 (en) 2011-04-08 2012-10-11 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method for increasing the replication capacity of an influenza virus in cultured cells
EP2710381A2 (en) 2011-05-16 2014-03-26 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods for screening substances capable of modulating the replication of an influenza virus
EP2734619B1 (en) * 2011-07-20 2017-09-06 BGP Products B.V. Process for producing orthomyxoviral antigen and vaccines
US20140328876A1 (en) 2011-11-18 2014-11-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
JP2015500864A (ja) * 2011-12-23 2015-01-08 ノバルティス アーゲー 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）に対して免疫するための安定な組成物
AU2013208693B2 (en) 2012-01-12 2017-12-07 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP4008354A1 (en) 2012-01-27 2022-06-08 Variation Biotechnologies Inc. Methods and compositions for therapeutic agents
US20130309700A1 (en) * 2012-05-21 2013-11-21 Celsis International Limited Methods, devices, and systems of detecting microorganisms
US9932620B2 (en) 2012-05-21 2018-04-03 Celsis Ltd. Methods, devices, and systems of detecting microorganisms
US9314519B2 (en) * 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
KR20140112255A (ko) 2013-03-13 2014-09-23 고려대학교 산학협력단 바이러스 생산능이 증가된 세포주 및 그 제조방법
CN105121634B (zh) 2013-03-13 2019-07-26 易木农麦克斯有限公司 具有提高的病毒生产能力的细胞系及其生产方法
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
WO2015017673A1 (en) * 2013-08-01 2015-02-05 Medimmune, Llc Methods for producing influenza vaccine compositions
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
US9579374B2 (en) 2013-12-04 2017-02-28 The Johns Hopkins University Method for rapidly designing pharmaceutical preparations for preventing viral infection
AR099470A1 (es) 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
TWI670085B (zh) * 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
WO2015151103A1 (en) * 2014-04-03 2015-10-08 Biondvax Pharmaceuticals Ltd. Compositions of multimeric-multiepitope influenza polypeptides and their production
US10526393B2 (en) 2014-06-18 2020-01-07 Immunomax Co., Ltd. Method for promoting virus infection and increasing virus production, by using cell line having lost BST2 gene functions
JP6655618B2 (ja) 2014-12-01 2020-02-26 トランジェーヌＴｒａｎｓｇｅｎｅ 安定な液体ワクシニアウイルス処方物
CN104984357B (zh) * 2015-06-02 2018-01-30 长春百克生物科技股份公司 不含明胶的疫苗保护剂组合物及流感减毒活疫苗
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
TW201720426A (zh) * 2015-11-27 2017-06-16 Nitto Denko Corp 流感疫苗乾燥製劑、及流感疫苗乾燥製劑之製造方法
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
WO2018184028A2 (en) 2017-03-31 2018-10-04 Terumo Bct, Inc. Cell expansion
JP2020519666A (ja) 2017-05-15 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 安定性のウイルス含有組成物
CA3062549A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
MX2020009262A (es) 2018-03-07 2021-01-08 Transgene Vectores de parapoxvirus.
WO2020136232A1 (en) 2018-12-28 2020-07-02 Transgene Sa Immunosuppressive m2 protein
US20220056481A1 (en) 2018-12-28 2022-02-24 Transgene M2-defective poxvirus
JP2022520443A (ja) * 2019-02-15 2022-03-30 セラム インスティチュート オブ インディア プライベイト リミテッド 弱毒生インフルエンザワクチン組成物及びその調製プロセス
AU2021233167A1 (en) * 2020-03-12 2022-09-22 Bavarian Nordic A/S Compositions improving poxvirus stability
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB660109A (en) * 1946-10-01 1951-10-31 American Cyanamid Co Improvements in or relating to the treatment of allantoic fluid containing a propagated virus together with non-viral proteins to obtain the virus in purified and viable from for use in a vaccine
US4158054A (en) * 1973-10-18 1979-06-12 Duncan Flockhart & Co. Ltd. Preparation of virus sub-unit vaccines
US3874999A (en) * 1973-10-31 1975-04-01 American Cyanamid Co Process for the purification of virus vaccine
US4000257A (en) * 1975-12-22 1976-12-28 American Cyanamid Company Process for the purification of influenza virus vaccine
US4057626A (en) 1976-10-08 1977-11-08 Richardson-Merrell Inc. Process for detoxifying influenza B virus
US4338296A (en) * 1979-10-16 1982-07-06 Smithkline-Rit Influenza virus and process of producing a vaccine therefrom
JPS57114527A (en) * 1979-10-29 1982-07-16 Merck & Co Inc Vaccine stabilizer
US4338335A (en) * 1980-02-05 1982-07-06 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
US4337242A (en) * 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
US4512972A (en) * 1980-06-30 1985-04-23 Kureha Chemical Industry Co., Ltd. Nasal preparation and processes for their production
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
US4512285A (en) * 1983-12-27 1985-04-23 Gof Manufacturing Company, Inc. Apparatus and method for egg turning during incubation
GB8914968D0 (en) 1989-06-29 1989-08-23 Connaught Lab Production of virus and purification of viral envelope proteins for vaccine use
DE69032102T2 (de) * 1989-08-15 1998-06-25 Massachusetts Inst Technology Stabilisierte impfstoffzusammensetzungen
AU2088992A (en) 1992-05-05 1993-11-11 Research Foundation For Microbial Diseases Of Osaka University, The Stabilized live vaccine
US7344722B1 (en) * 1993-06-29 2008-03-18 The Regents Of The University Of Michigan Cold-adapted influenza virus
US5824536A (en) 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
US6146873A (en) 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
AU4161296A (en) 1995-10-20 1997-05-07 Davidson, Clifford M. Influenza vaccine
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6177082B1 (en) * 1998-08-13 2001-01-23 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
WO2000035481A2 (en) 1998-12-17 2000-06-22 Connaught Laboratories Limited Multivalent immunogenic composition containing rsv subunit composition and influenza virus preparation
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
AU1593001A (en) * 1999-11-12 2001-06-06 Fibrogen, Inc. Recombinant gelatin in vaccines
CN1147316C (zh) * 2000-03-16 2004-04-28 辽宁天成生物制药研究所 流感病毒静水压技术灭活工艺制备疫苗的方法
KR100848719B1 (ko) 2000-04-28 2008-07-25 세인트 쥬드 칠드런즈 리써치 호스피탈 감염성 인플루엔자 바이러스 생성용 ｄｎａ 트랜스펙션시스템
BRPI0002694C1 (pt) 2000-06-19 2021-05-25 Fund Butantan processo de obtenção de vacina contra raiva em células vero, para uso humano
WO2002024876A2 (en) 2000-09-25 2002-03-28 Polymun Scientific Immunbiologische Forschung Gmbh Live influenza vaccine and method of manufacture
DE60239594D1 (de) 2001-02-23 2011-05-12 Glaxosmithkline Biolog Sa Influenza vakzinzusammensetzungen zur intradermaler verabreichung
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
EP1528937B1 (en) * 2001-06-05 2016-08-10 The Regents Of The University Of Michigan Nanoemulsion vaccines
US7195905B2 (en) 2001-12-10 2007-03-27 Baxter Healthcare S.A. Enveloped virus vaccine and method for production
US7258873B2 (en) * 2002-04-11 2007-08-21 Medimmune Vaccines, Inc. Preservation of bioactive materials by spray drying
EP2591771A1 (en) * 2002-04-11 2013-05-15 MedImmune, LLC Preservation of bioactive materials by freeze dried foam
KR101229202B1 (ko) 2002-04-26 2013-02-01 메디뮨 엘엘씨 인플루엔자 바이러스의 생산을 위한 다중 플라스미드 시스템
CA2508592A1 (en) 2002-12-17 2004-07-15 Medimmune Vaccines, Inc. High pressure spray-dry of bioactive materials
KR101251902B1 (ko) 2003-02-25 2013-04-08 메디뮨 엘엘씨 인플루엔자 백신 조성물의 제조 방법
US20060110406A1 (en) * 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
JP4771959B2 (ja) 2003-12-23 2011-09-14 メディミューン，エルエルシー インフルエンザウイルス作製のための多重プラスミド系
DK1748790T3 (en) 2004-05-24 2015-10-19 Medimmune Llc Multiplasmidsystem for the production of influenza
WO2006041819A1 (en) 2004-10-06 2006-04-20 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions

Also Published As

Publication number Publication date
KR20130064826A (ko) 2013-06-18
AU2008230033B2 (en) 2012-01-12
JP2006519028A (ja) 2006-08-24
CN1777687A (zh) 2006-05-24
AU2008230033A1 (en) 2008-11-13
KR101251902B1 (ko) 2013-04-08
WO2005014862B1 (en) 2005-06-16
KR101357443B1 (ko) 2014-02-06
JP4617300B2 (ja) 2011-01-19
CN101804202A (zh) 2010-08-18
US20090246225A1 (en) 2009-10-01
AU2004263813B2 (en) 2008-08-14
AU2004263813A1 (en) 2005-02-17
EP2481819A1 (en) 2012-08-01
US7262045B2 (en) 2007-08-28
EP1597400A1 (en) 2005-11-23
CN100582244C (zh) 2010-01-20
KR101190932B1 (ko) 2012-10-16
CA2517181A1 (en) 2005-02-17
KR20120087892A (ko) 2012-08-07
CA2517181C (en) 2013-07-16
CN101804202B (zh) 2014-06-18
US20160051660A1 (en) 2016-02-25
US20130189305A1 (en) 2013-07-25
KR20120103737A (ko) 2012-09-19
EP1597400A4 (en) 2007-09-05
KR101360300B1 (ko) 2014-02-13
EP1597400B8 (en) 2013-10-09
US8986705B2 (en) 2015-03-24
KR20050114625A (ko) 2005-12-06
WO2005014862A1 (en) 2005-02-17
US20070161085A1 (en) 2007-07-12
AU2004263813B8 (en) 2008-09-11
CA2807534A1 (en) 2005-02-17
US20040265987A1 (en) 2004-12-30
EP1597400B1 (en) 2012-08-22

Similar Documents

Publication Publication Date Title
HK1077085A1 (en) Methods of producing influenza vaccine compositions
PT1824990E (pt) Métodos de produção de composições de vacinas contra a gripe
HK1201720A1 (en) Refrigerator-temperature stable influenza vaccine compositions
EP1603590A4 (en) INFLUENZA VIRUS VACCINE
ZA200609543B (en) Process for the production of an influenza vaccine
HK1067891A1 (en) Influenza vaccine composition
GB0321607D0 (en) Manufacture of pharmaceutical compositions
EP1708748A4 (en) INFLUENZA IMMUNOGENS AND VACCINES
GB0323965D0 (en) Immunogenic compositions
SI1524993T1 (sl) Neisserijski vakcinski sestavki, ki obsegajo kombinacijo antigenov
ZA200602948B (en) Immunogenic compositions
ZA200706158B (en) PCV2 immunogenic compositions and methods of producing such compositions
EP1745573A4 (en) PROCESS FOR PREPARING 2-DEOXY-BETA-L-NUCLEOSIDES
IS7261A (is) N-adamantýlmetýlafleiður og milliefni sem lyfjablöndur og aðferðir til að framleiða þær
HK1214534A1 (zh) 流感疫苗
HUE046045T2 (hu) PCV2 immunogén készítmények és eljárások ilyen készítmények elõállítására
HK1088827A1 (en) Method of obtaining cochlear structures, vaccine compositions, adjuvants and intermediates thereof
GB0501008D0 (en) Method of producing conjugate vaccines
EP1625136A4 (en) PROCESS FOR PREPARING 4-R-SUBSTITUTED 4-DEMETHOXYDAUNORUBICIN
ITMI20031994A1 (it) Procedimento per la preparazione di fludarabina fosfato
HK1087630A1 (en) Subcutaneously-administered ganglioside-based vaccine compositions
GB0300455D0 (en) Meyhod of vaccine preparation
HK1151227A1 (en) Novel oral formulations of ospemifene
GB0400633D0 (en) Method of vaccine preparation
GB0500932D0 (en) Method of vaccine preparation

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20240224